Giving a skin cancer diagnosis to a patient is never easy. The word 'cancer' is a scary word for any
patient to hear. Sadly, one in five Americans will develop skin cancer over the course of their
lifetime and 40 to 50 percent of Americans who live to age 65 will have either basal cell carcinoma
or squamous cell carcinoma at least once. Basal cell cancer is the most common form of skin
cancer.
While patients facing basal cell cancer have multiple choices available for the treatment of their
skin cancer, are you offering your patients the best treatment available? The majority of treatment
options for basal cell cancer involve a surgical procedure of some type, whether excisional surgery,
electrosurgery, cryosurgery, laser surgery or Mohs micrographic surgery.
What if you could provide your patients facing skin cancer with a treatment option that is painless,
safe and effective to treat his or her basal cell carcinoma?
The SRT-100™ is that option.
Sensus Healthcare's SRT-100™ delivers a precise, calibrated dose of Superficial Radiation Therapy
that only goes skin deep. This low-dose of radiation safely destroys non-melanoma skin cancer
(such as basal cell carcinoma) without damaging healthy surrounding tissue. There is no need for
anesthesia, no cutting or stitching, less risk for infection, and no need for patients to undergo
reconstructive plastic surgery to repair surgical scars. With the SRT-100™, patients heal quickly
from their basal cell cancer treatment with no downtime or lifestyle restrictions following the
procedure.
Performed right in your office, Superficial Radiation Therapy with the SRT-100™ delivers optimum
results to treat basal cell carcinoma without the negative side effects of invasive treatments. This
treatment is ideal for your patients diagnosed with basal cell carcinoma who also have health risks
that prevent them from undergoing surgical treatment, or patients who wish to avoid the pain and
scarring associated with surgery.
For the physician, SRT-100™ offers many unique features including: broad range of motion;
compact, mobile design; precise and accurate x-ray delivery; variable applicator sizes; and
replaceable contact shields.
Sensus Healthcare's SRT-100™ has cure rates comparable to those of surgical skin cancer
treatment options and has been cleared by the U.S. Food and Drug Administration for the
treatment of basal cell carcinoma. It is ideal for private dermatology and oncology practices, as
well as hospitals and multi-locale healthcare providers.
Give your patients a non-surgical, painless and effective basal cell cancer treatment. Contact
Sensus Healthcare today to learn more about the SRT-100™.
Sensus Healthcare Inc. published this content on 17 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 17 January 2017 19:16:03 UTC.
Original documenthttp://sensushealthcare.com/blog/srt-100-doctors-choice-treatment-non-melanoma-basal-cell-cancer/
Public permalinkhttp://www.publicnow.com/view/1B9998614AB29A6C3A58FDE445DB3F2BD56F46C2